1. GPCR/G Protein
  2. Glucagon Receptor

Taspoglutide (Synonyms: ITM077; R1583; BIM51077)

Cat. No.: HY-P0165 Purity: 96.85%
Handling Instructions

Taspoglutide is a long-acting glucagon-like peptide 1 (GLP-1) receptor agonist developed for treatment of type 2 diabetes, with an EC50 value of 0.06 nM.

For research use only. We do not sell to patients.
Taspoglutide Chemical Structure

Taspoglutide Chemical Structure

CAS No. : 275371-94-3

Size Price Stock Quantity
10 mM * 1 mL in DMSO USD 1763 In-stock
1 mg USD 132 In-stock
5 mg USD 396 In-stock
10 mg USD 600 In-stock
25 mg USD 1200 In-stock
50 mg   Get quote  
100 mg   Get quote  

* Please select Quantity before adding items.

Customer Review

  • Biological Activity

  • Protocol

  • Technical Information

  • Purity & Documentation

  • References


Taspoglutide is a long-acting glucagon-like peptide 1 (GLP-1) receptor agonist developed for treatment of type 2 diabetes, with an EC50 value of 0.06 nM.

IC50 & Target

EC50: 0.06 nM (GLP-1)[1]

In Vitro

Taspoglutide (R1583/BIM51077) is a long acting 10% formulation of (Aib8-35) human GLP-1 (7-36 amides) with 93% homology with the native polypeptide. It activates the GLP-1 receptor. Taspoglutide has comparable affinity (affinity constant 1.1±0.2 nM) to the natural ligand (affinity constant 1.5±0.3 nM) for the hGLP-1 receptor and exhibits comparable potency in stimulating cAMP production[2].

In Vivo

Taspoglutide has been shown to enhance the rate of glucose-induced insulin secretion from isolated, cultured rat islets and the perfused ZDF rat pancreas. Taspoglutide in Sprague-Dawley rats and diabetic db/db mice have shown a dose-related enhancement of glucose-dependent insulin release, which lower blood glucose in the db/db mouse model of type 2 diabetes[3]. Acute treatment with taspoglutide reduces glucose excursion and increased insulin response during oGTT. In chronically treated rats, glucose excursion and levels of GIP, PYY and triglycerides during oGTT on day 21 are significantly reduced[4]. Hepatic triglyceride levels are significantly reduced in livers from taspoglutide-treated. Taspoglutide does not reduce plaque area or lipid content in the aortic arch or abdominal aorta, and no significant change in aortic macrophage accumulation is detected after taspoglutide or metformin mice[5].

Clinical Trial
Preparing Stock Solutions
Concentration Volume Mass 1 mg 5 mg 10 mg
1 mM 0.2994 mL 1.4971 mL 2.9943 mL
5 mM 0.0599 mL 0.2994 mL 0.5989 mL
10 mM 0.0299 mL 0.1497 mL 0.2994 mL
Please refer to the solubility information to select the appropriate solvent.
Animal Administration

Taspoglutide is prepared in saline.

Rats: The Zucker diabetic fatty (ZDF) rats (animal model of type 2 diabetes) are used in the study. ZDF rats are treated acutely (0.1, 1, 10 μg/kg) or chronically (sustained-release of 1 mg) with a single long-acting dose of taspoglutide. Pioglitazone is used as a positive control in the chronic study. Postprandial glucose, body weight, glycaemic control and insulin sensitivity are assessed over 21 days in chronically treated animals[4].

Mice: High-fat diet-fed male ApoE-/- mice are used in the study. Mice with glucose levels from 15-25 mM are then randomized to different groups and treated for 12 wk with a once-monthly sc 0.4-mg taspoglutide microtablet suspension, a sc placebo microtablet, or metformin (400 mg/kg*d) continuously provided in the drinking water plus a sc placebo microtablet[5].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Molecular Weight







O=C(N[[email protected]@H](CC(C)C)C(N[[email protected]@H](C(C)C)C(N[[email protected]@H](CCCCN)C(NC(C)(C)C(N[[email protected]](C(N)=O)CCCNC(N)=N)=O)=O)=O)=O)[[email protected]@H](NC([[email protected]](C)NC([[email protected]@]([[email protected]@H](C)CC)([H])NC([[email protected]@H](NC([[email protected]](CCC(O)=O)NC([[email protected]](CCCCN)NC([[email protected]](C)NC([[email protected]](C)NC([[email protected]](CCC(N)=O)NC(CNC([[email protected]](CCC(O)=O)NC([[email protected]](CC(C)C)NC([[email protected]@H](NC([[email protected]](CO)NC([[email protected]](CO)NC([[email protected]](C(C)C)NC([[email protected]](CC(O)=O)NC([[email protected]](CO)NC([[email protected]@]([[email protected]](O)C)([H])NC([[email protected]@H](NC([[email protected]@]([[email protected]](O)C)([H])NC(CNC([[email protected]](CCC(O)=O)NC(C(C)(C)NC([[email protected]@H](N)CC1=CN=CN1)=O)=O)=O)=O)=O)CC2=CC=CC=C2)=O)=O)=O)=O)=O)=O)=O)CC3=CC=C(O)C=C3)=O)=O)=O)=O)=O)=O)=O)=O)=O)CC4=CC=CC=C4)=O)=O)=O)CC5=CNC6=CC=CC=C56

Powder -20°C 3 years
  4°C 2 years
In solvent -80°C 6 months
  -20°C 1 month

Room temperature in continental US; may vary elsewhere

Solvent & Solubility

DMSO: ≥ 28 mg/mL

* "<1 mg/mL" means slightly soluble or insoluble. "≥" means soluble, but saturation unknown.

Inquiry Online

Your information is safe with us. * Required Fields.

Product name



Applicant name *


Email address *

Phone number *


Organization name *

Country *


Requested quantity *


Bulk Inquiry

Inquiry Information

Product Name:
Cat. No.: